Bubble Wrap maker Sealed Air surges on report of buyout talks
Investing.com -- Monopar Therapeutics Inc. (NASDAQ:MNPR) stock gained 4.1% in premarket trading Monday following the company’s presentation of new data showing improved copper balance in Wilson disease patients treated with tiomolybdate choline.
The clinical-stage biopharmaceutical company presented the results from its Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases meeting in Washington, D.C. The data demonstrated that treatment with ALXN1840 (tiomolybdate choline) led to rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion.
According to the presentation, patients treated with ALXN1840 showed significantly lower mean daily copper balance compared to their pre-treatment baseline. Improvements were observed both during the initial 15 mg once-daily dosing period and over the entire treatment duration.
The presented data aligned with findings published in The Journal of Hepatology in September 2025, which provided a new analysis showing ALXN1840 rapidly improves copper balance in Wilson disease patients.
Following the data presentation, Chardan Capital Markets analyst Keay Nakae raised his price target on Monopar to $100 from $85 while maintaining a Buy rating.
The positive market reaction comes despite AstraZeneca’s previous decision to terminate development of this program in 2023, citing less clear data from this and another phase II mechanistic study, despite ALXN1840 achieving its primary efficacy endpoint in a phase III clinical trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.